1887

Abstract

Equine sarcoids are common therapy-resistant skin tumours induced by bovine papillomavirus type 1 or 2 (BPV1, BPV2) infection. We have previously shown that prophylactic vaccination with BPV1 L1 virus-like particles (VLPs) efficiently protects horses from experimental BPV1-induced pseudo-sarcoid development. Here, we assessed BPV1 L1 VLP vaccine-mediated long-term protection from experimental tumour formation in seven horses 5 years after immunization with three different doses of BPV1 L1 VLPs, and three unvaccinated control animals. Horses were challenged by intradermal inoculation with infectious BPV1 virions at 10 sites on the neck (10 virions per injection). In vaccinated horses, BPV1 challenge did not result in any apparent lesions irrespective of vaccine dosage and BPV1-neutralizing antibody titres that had dropped considerably over time and below the detection limit in one individual. Control horses developed pseudo-sarcoids at all inoculation sites. We conclude that immunization of horses with BPV1 L1 VLPs induces long-lasting protection against experimental BPV1 virion-induced disease.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000791
2017-06-01
2019-12-14
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/6/1329.html?itemId=/content/journal/jgv/10.1099/jgv.0.000791&mimeType=html&fmt=ahah

References

  1. Kidney BA, Berrocal A. Sarcoids in two captive tapirs (Tapirus bairdii): clinical, pathological and molecular study. Vet Dermatol 2008;19:380–384 [CrossRef][PubMed]
    [Google Scholar]
  2. Roperto S, Russo V, Ozkul A, Sepici-Dincel A, Maiolino P et al. Bovine papillomavirus type 2 infects the urinary bladder of water buffalo (Bubalus bubalis) and plays a crucial role in bubaline urothelial carcinogenesis. J Gen Virol 2013;94:403–408 [CrossRef][PubMed]
    [Google Scholar]
  3. Silvestre O, Borzacchiello G, Nava D, Iovane G, Russo V et al. Bovine papillomavirus type 1 DNA and E5 oncoprotein expression in water buffalo fibropapillomas. Vet Pathol 2009;46:636–641 [CrossRef][PubMed]
    [Google Scholar]
  4. Williams JH, van Dyk E, Nel PJ, Lane E, van Wilpe E et al. Pathology and immunohistochemistry of papillomavirus-associated cutaneous lesions in Cape mountain zebra, giraffe, sable antelope and African buffalo in South Africa. J S Afr Vet Assoc 2011;82:97–106 [CrossRef][PubMed]
    [Google Scholar]
  5. Hainisch EK, Brandt S. Sarcoids. In Robinson NE, Sprayberry KA. (editors) Robinson's Current Therapy in Equine Medicine, 7th ed. St. Louis, Missouri, USA: Saunders Elsevier; 2015; pp.Chapter 99
    [Google Scholar]
  6. Carr EA, Théon AP, Madewell BR, Griffey SM, Hitchcock ME. Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States. Am J Vet Res 2001;62:741–744 [CrossRef][PubMed]
    [Google Scholar]
  7. Lunardi M, de Alcântara BK, Otonel RA, Rodrigues WB, Alfieri AF et al. Bovine papillomavirus type 13 DNA in equine sarcoids. J Clin Microbiol 2013;51:2167–2171 [CrossRef][PubMed]
    [Google Scholar]
  8. Campo MS. Bovine papillomavirus: old system, new lessons?. In Campo MS. (editor) Papillomavirus Research: From Natural History to Vaccines and Beyond Norfolk, UK: Caister Academic Press; 2006; pp.373–387
    [Google Scholar]
  9. Scott DW, Miller W. Sarcoid. In Scott DW, Miller WH Jr. (editors) Equine Dermatology St. Louis, Missouri, USA: Saunders Elsevier; 2003; pp.719–731
    [Google Scholar]
  10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180–12184 [CrossRef][PubMed]
    [Google Scholar]
  11. Hainisch EK, Brandt S, Shafti-Keramat S, van den Hoven R, Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. Equine Vet J 2012;44:107–111 [CrossRef][PubMed]
    [Google Scholar]
  12. Hartl B, Hainisch EK, Shafti-Keramat S, Kirnbauer R, Corteggio A et al. Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcoid formation. J Gen Virol 2011;92:2437–2445 [CrossRef][PubMed]
    [Google Scholar]
  13. Olson C, Cook RH. Cutaneous sarcoma-like lesions of the horse caused by the agent of bovine papilloma. Proc Soc Exp Biol Med 1951;77:281–284 [CrossRef][PubMed]
    [Google Scholar]
  14. Ragland WL, Spencer GR. Attempts to relate bovine papilloma virus to the cause of equine sarcoid: equidae inoculated intradermally with bovine papilloma virus. Am J Vet Res 1969;30:743–752[PubMed]
    [Google Scholar]
  15. Voss JL. Transmission of equine sarcoid. Am J Vet Res 1969;30:183–191[PubMed]
    [Google Scholar]
  16. Hainisch EK, Abel-Reichwald H, Shafti-Keramat S, Pratscher B, Corteggio A et al. Potential of a BPV1 L1 VLP vaccine to prevent BPV1- or BPV2-induced pseudo-sarcoid formation and safety and immunogenicity of EcPV2 L1 VLPs in the horse. J Gen Virol 2017;98:230–241 [CrossRef][PubMed]
    [Google Scholar]
  17. Brandt S, Haralambus R, Schoster A, Kirnbauer R, Stanek C. Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. J Gen Virol 2008;89:1390–1395 [CrossRef][PubMed]
    [Google Scholar]
  18. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B. et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin 2011;7:1359–1373 [CrossRef][PubMed]
    [Google Scholar]
  19. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B. et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7:1343–1358 [CrossRef][PubMed]
    [Google Scholar]
  20. Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC et al. Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Hum Vaccin Immunother 2014;10:3446–3454 [CrossRef][PubMed]
    [Google Scholar]
  21. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996;70:960–965[PubMed]
    [Google Scholar]
  22. Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L et al. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 2001;19:2783–2792 [CrossRef][PubMed]
    [Google Scholar]
  23. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011;85:13253–13259 [CrossRef][PubMed]
    [Google Scholar]
  24. Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008;26:6844–6851 [CrossRef][PubMed]
    [Google Scholar]
  25. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines–immune responses. Vaccine 2012;30:F83–F87 [CrossRef][PubMed]
    [Google Scholar]
  26. Nasir L, Reid SWJ. Bovine papillomaviruses and equine sarcoids. In Campo MS. (editor) Papillomavirus Research: From Natural History to Vaccines and Beyond Norfolk, UK: Caister Academic Press; 2006; pp.389–397
    [Google Scholar]
  27. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008;109:S15–S21 [CrossRef][PubMed]
    [Google Scholar]
  28. Mueller SN, Mackay LK. Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol 2016;16:79–89 [CrossRef][PubMed]
    [Google Scholar]
  29. de Bruijn ML, Greenstone HL, Vermeulen H, Melief CJ, Lowy DR et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 1998;250:371–376 [CrossRef][PubMed]
    [Google Scholar]
  30. Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003;188:327–338 [CrossRef][PubMed]
    [Google Scholar]
  31. Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006;353:451–462 [CrossRef][PubMed]
    [Google Scholar]
  32. Brandt S, Tober R, Corteggio A, Burger S, Sabitzer S et al. BPV-1 infection is not confined to the dermis but also involves the epidermis of equine sarcoids. Vet Microbiol 2011;150:35–40 [CrossRef][PubMed]
    [Google Scholar]
  33. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC et al. Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity. Nature 2012;483:227–231 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000791
Loading
/content/journal/jgv/10.1099/jgv.0.000791
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error